Safety First: Considerations for Emerging Modalities and Adjunct Therapies

Course overview

UAN: 0018-0000-19-300-H04-P & T RELEASE: 08/29/2019 EXPIRE: 08/29/2019 CREDITS: 2.25 LEARNING OBJECTIVES: 1. Describe the emerging modality of PETMR and how it compares to the current PET/CT imaging process. 2. Discuss patient and provider safety of the emerging modality of PETMR 3. Explain the patient safety considerations of adjunct therapies (gadolinium, morphine, diphenhydramine, adenosine, Lexiscan and DATScan). 4. Identify other drug interactions with emerging modality of PET/MRI NOTE: An annual subscription for Purdue's nuclear pharmacy re-certification program provides access to both the continuing education component of the program and the "Radiopharmacy Portal" a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $195 for nuclear pharmacists and $95 for nuclear pharmacy technicians.